# US 2015/0361164 A1 · HUMANIZED ANTl-HMGB1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0361164 A1
- Document ID: US20150361164A1
- Status: Published application
- Kind: A1
- Application number: 14/761,152
- Filed: 2013-12-06
- Published: 2015-12-17
- Earliest claimed: 2013-01-28
- Assignees: Evec Inc.; National University Corporation Okayama Universtity
- Applicants: Evec Inc.; National University Corporation Okayama Universtity
- Inventors: Kenzo TAKADA; Takashi TORASHIMA; Masahiro NISHIBORl
- Web page: https://patentgrep.com/patent/US20150361164A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07K 16/24: against cytokines, lymphokines or interferons
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.

## Claims

### Claim 1

A humanized antibody specifically binding to an amino acid sequence (EEEDDDDE (SEQ ID NO: 60)) present in the C-terminal domain of HMGB1 protein, or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein
(i) the heavy chain variable region (VH) comprises:
(a) an amino acid sequence of heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO: 7,
(b) an amino acid sequence of heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 8 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO: 8; and
(c) an amino acid sequence of heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO: 9, and
(ii) the light chain variable region (VL) comprises:
(a) an amino acid sequence of light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO: 10,
(b) an amino acid sequence of light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO: 11; and
(c) an amino acid sequence of light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO: 12.

### Claim 2 (depends on 1)

The humanized antibody or antigen-binding fragment thereof according to claim 1, wherein
(i) the heavy chain variable region (VH) comprises:
(a) an amino acid sequence of heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7,
(b) an amino acid sequence of heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 8; and
(c) an amino acid sequence of heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, and
(ii) the light chain variable region (VL) comprises:
(a) an amino acid sequence of light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10,
(b) an amino acid sequence of light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11; and
(c) an amino acid sequence of light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12.

### Claim 3 (depends on 1)

The humanized antibody or antigen-binding fragment thereof of claim 1, wherein
(i) the heavy chain variable region (VH) comprises the amino acid sequences of SEQ ID NOs: 43, 44, 45 and 46 as amino acid sequences of FR1, FR2, FR3 and FR4, respectively, wherein the amino acid sequences of FR1, FR2, FR3 and FR4 optionally have mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequences of SEQ ID NOs: 43, 44, 45 and 46, respectively, and
(ii) the light chain variable region (VL) comprises the amino acid sequences of SEQ ID NOs: 47, 48, 49 and 50 as amino acid sequences of FR1, FR2, FR3 and FR4, respectively, wherein the amino acid sequences of FR1, FR2, FR3 and FR4 optionally have mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequences of SEQ ID NOs: 47, 48, 49 and 50, respectively.

### Claim 4 (depends on 1)

The humanized antibody or antigen-binding fragment thereof of claim 1, wherein
(i) the heavy chain variable region (VH) comprises an amino acid sequence in which at least the two amino acid residues at positions 49 and 94 are amino acid residues (which are each alanine) derived from the rat antibody #10-22 H chain, and
(ii) the light chain variable region (VL) comprises an amino acid sequence in which at least the two amino acid residues at positions 44 and 46 are amino acid residues (which are isoleucine and arginine, respectively) derived from the rat antibody #10-22 L chain.

### Claim 5 (depends on 1)

The humanized antibody or antigen-binding fragment thereof of claim 1, wherein
(i) the heavy chain variable region (VH) comprises an amino acid sequence having a 90% or more identity with the amino acid sequence of SEQ ID NO: 41, and
(ii) the light chain variable region (VL) comprises an amino acid sequence having a 90% or more identity with the amino acid sequence of SEQ ID NO: 42.

### Claim 6 (depends on 1)

The humanized antibody or antigen-binding fragment thereof of claim 1, wherein
(i) the heavy chain variable region (VH) comprises the amino acid sequence of SEQ ID NO: 41, and
(ii) the light chain variable region (VL) comprises the amino acid sequence of SEQ ID NO: 42.

### Claim 7 (depends on 1)

The humanized antibody or antigen-binding fragment thereof of claim 1, wherein the class (subclass) of the humanized antibody is IgG1(λ) or IgG2(λ).

### Claim 8 (depends on 1)

The humanized antibody or antigen-binding fragment thereof of claim 1, wherein the binding activity thereof to human HMGB1 protein (analyzed by ELISA assay) is 2-fold or higher than that of #10-22 chimeric antibody when compared at 250 ng/ml.

### Claim 9 (depends on 1)

The humanized antibody or antigen-binding fragment thereof of claim 1, wherein the activity thereof required for 50% inhibition (IC50) of binding of human HMGB1 protein to RAGE is 5 μg/mL (about 33 nM) or less.

### Claim 10 (depends on 1)

The antibody or antigen-binding fragment thereof of claim 1, wherein the activity thereof required for 50% inhibition (IC50) of HMGB1 protein-stimulated TNF-α release in human PBMCs is 0.02 μg/mL (about 0.13 nM) or less.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising the humanized antibody or antigen-binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11 for use in treatment or prevention of an HMGB1-related diseases induced by HMGB1 released from cells.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10 for use in treatment or prevention of a HMGB1-related disease, wherein the HMGB1-related disease is any one of cerebral infarction, cerebral edema, cerebral vasospasm, traumatic brain damage, atherosclerosis, neuropathic pain, sepsis, arthritis, acute lung trauma, cerebral ischemia, renal ischemia, and hepatic ischemia.

### Claim 14 (depends on 1)

An isolated nucleic acid encoding the amino acid sequence of the humanized antibody or antigen-binding fragment thereof of claim 1, or an isolated nucleic acid hybridizable with any of these nucleic acids under high stringent conditions.

### Claim 15 (depends on 14)

A recombinant expression vector comprising the isolated nucleic acid according to claim 14.

### Claim 16 (depends on 15)

A host cell transformed with the recombinant expression vector according to claim 15.
